Is Abbott’s January Pullback a Good Time to Buy? Abbott Laboratories' January price pullback is a signal to load up on shares; this Dividend Aristocrat is growing its business and driving cash flow. MarketBeat · Jan 24
How Authentic Was Abbott Elementary In Relocating The Cast To An Abandoned Mall? Janelle James Opened Up About ‘Lots Of Smells’ At least the animatronic Ben Franklin head is dead! Cinemablend · Jan 22
2 Healthcare Names That Could Get a Big Boost From Earnings Both Abbott Laboratories and Intuitive Surgical report fourth-quarter results in late January—and both companies offer investors multiple reasons to be bullish. MarketBeat · Jan 20
Fortune 500 exec: College grads aren't ready for today's jobs There's a missing link between college and career. Fortune · Jan 17
With Abbott Elementary Nominated For Major Awards, The Stars Opened Up About Representing Traditional Sitcoms Against Streaming Competition Will Abbott Elementary score in the awards circuit this year? Cinemablend · Jan 4
This Dividend Stock Just Scored an FDA Win. Should You Buy Shares Now? Abbott’s latest regulatory progress supports its durable growth narrative. Is now the right time to revisit ABT shares? Barchart · Dec 23, 2025
Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength Broadcom, Abbott, and Nordic American raised dividends, offering strong yields and long-term upside despite market volatility and sector headwinds. MarketBeat · Dec 22, 2025
Abbott Elementary's Mid-Season Finale Featured Its Craziest Plot Twist, And I Can't Stop Thinking About The Silly Repercussions It Could Have I cannot believe this really happened! Cinemablend · Dec 11, 2025
FDA Warns Against Abbott Glucose Monitor Sensors After Reports Of Over 700 Injuries, 7 Deaths The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries. Benzinga · Dec 5, 2025
Faulty glucose monitors linked to 7 deaths and more than 700 injuries worldwide. Here’s what we know The sensors provide real-time measurements of sugar levels in the blood, sending that data wirelessly to a device or phone. Euronews · Dec 5, 2025
Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns The U.S. Food and Drug Administration warned people to stop using certain types of glucose monitor sensors that were linked to seven deaths The Independent UK · Dec 4, 2025
7 deaths linked to faulty glucose monitors put in people’s arms, FDA says About three million devices are affected, though many may be expired or already used The Independent UK · Dec 3, 2025
Is Abbott Laboratories Stock Underperforming the S&P 500? Abbott Laboratories has lagged behind the S&P 500 in recent months as well as over the past year, yet analysts remain strongly bullish on the stock’s prospects. Barchart · Nov 26, 2025
How This 'Hidden Gold Mine' Has Beaten The Market For 30 Years For three decades, I have watched investors chase the latest hot stock, the newest tech darling, and the most hyped IPO. Meanwhile, a sleepy corner of the market has been quietly minting fortunes. Benzinga · Nov 24, 2025
Benzinga · Nov 21, 2025 Deal Dispatch: Abbott, TPG And Lonza Make Major Moves, M&M Custard And New Fortress Energy Struggle For the previous edition of Deal Dispatch, click here.
Woman & Home · Nov 21, 2025 Our fashion team has been hunting Black Friday fashion deals for years – here are the 24 items we really rate Plenty of brands have already dropped major Black Friday discounts, and these are items worth shopping right now
Barchart · Nov 20, 2025 Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here? Exact Sciences stock rallies as Abbott announces a $21 billion deal to acquire to the molecular diagnostics firm. Here’s why EXAS shares are unlikely to push any higher in 2026.
International Business Times UK · Nov 20, 2025 Abbott-Exact Sciences Deal Set to Shake Up Diagnostic Market with Cancer-Fighting Acquisition Rumours fly that Abbott is very close to sealing the deal to acquire cancer treatment champion Exact Sciences.
Benzinga · Nov 20, 2025 Abbott's $21 Billion Exact Sciences Buyout Reshapes Cancer Diagnostics Abbott Laboratories (NYSE:ABT) agreed on Thursday to acquire cancer screening company Exact Sciences Corp (NASDAQ:EXAS) for $105 per common share, representing a total equity value of approximately $21 billion and an estimated enterprise value of $23 billion.
Cinemablend · Nov 15, 2025 The Paper Is A Blast, And I Want A Specific Crossover With Abbott Elementary Hear me out.
Benzinga · Nov 10, 2025 The Insider Report: The Bears Have Been Poked – Will They Fall Back Asleep? Stocks dropped hard last week, but a late-day rally on Friday staved off the worst. The Dow Jones Industrial Average held up the best, only closing down 1.21%. The SP 500 was down 1.63%, but the Nasdaq suffered the most, as it closed down 3.04%. Tech was routed hard as…
The Independent UK · Nov 9, 2025 Preliminary tests find germ that causes botulism in ByHeart baby formula California health officials say tests showed that ByHeart baby formula linked to a botulism outbreak contained the type of bacteria that produces the toxin that has sickened at least 13 infants in 10 states
Barchart · Nov 6, 2025 Abbott Laboratories Stock Outlook: Is Wall Street Bullish or Bearish? Despite underperforming the broader market over the past year, Wall Street analysts remain highly bullish on Abbott Laboratories' long-term outlook.
Barchart · Oct 17, 2025 5 Dividend Aristocrats Proving That Reliability Still Pays in 2025 These five companies offer stability in terms of growth and income.
MarketBeat · Oct 17, 2025 Abbott Laboratories' October Price Plunge Is a Signal to Buy Abbott Laboratories is on track to reach new highs, potentially by early 2026, opening the door for a 30% stock price increase in addition to the dividend.